Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 3485785, 11 pages
https://doi.org/10.1155/2017/3485785
Review Article

Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease

1Department of Health Sciences, Oita University of Nursing and Health Sciences, Oita, Japan
2Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima, Japan
3Division of Nephrology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan

Correspondence should be addressed to Masafumi Fukagawa

Received 31 October 2016; Revised 28 February 2017; Accepted 13 March 2017; Published 22 March 2017

Academic Editor: Wen-Chin Lee

Copyright © 2017 Yoshiko Iwasaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Alem, D. J. Sherrard, D. L. Gillen et al., “Increased risk of hip fracture among patients with end-stage renal disease,” Kidney International, vol. 58, no. 1, pp. 396–399, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Coco and H. Rush, “Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone,” American Journal of Kidney Diseases, vol. 36, no. 6, pp. 1115–1121, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. T. L. Nickolas, D. J. McMahon, and E. Shane, “Relationship between moderate to severe kidney disease and hip fracture in the United States,” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 3223–3232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. K. E. Ensrud, L.-Y. Lui, B. C. Taylor et al., “Renal function and risk of hip and vertebral fractures in older women,” Archives of Internal Medicine, vol. 167, no. 2, pp. 133–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Jamal, D. C. Bauer, K. E. Ensrud et al., “Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial,” Journal of Bone and Mineral Research, vol. 22, no. 4, pp. 503–508, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. F. Fried, M. L. Biggs, M. G. Shlipak et al., “Association of kidney function with incident hip fracture in older adults,” Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 282–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Dooley, N. S. Weiss, and B. Kestenbaum, “Increased risk of hip fracture among men with CKD,” American Journal of Kidney Diseases, vol. 51, no. 1, pp. 38–44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Trombetti, F. Herrmann, P. Hoffmeyer, M. A. Schurch, J. P. Bonjour, and R. Rizzoli, “Survival and potential years of life lost after hip fracture in men and age-matched women,” Osteoporosis International, vol. 13, no. 9, pp. 731–737, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Haentjens, J. Magaziner, C. S. Colón-Emeric et al., “Meta-analysis: excess mortality after hip fracture among older women and men,” Annals of Internal Medicine, vol. 152, no. 6, pp. 380–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Mittalhenkle, D. L. Gillen, and C. O. Stehman-Breen, “Increased risk of mortality associated with hip fracture in the dialysis population,” American Journal of Kidney Diseases, vol. 44, no. 4, pp. 672–679, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. C.-F. Lin and W.-M. Liang, “Mortality and complications after hip fracture among elderly patients undergoing hemodialysis,” BMC Nephrology, vol. 16, no. 1, article 100, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. C.-H. Kuo, T.-C. Hsieh, C.-H. Wang et al., “Increased risks of mortality and atherosclerotic complications in incident hemodialysis patients subsequently with bone fractures: a nationwide case-matched cohort study,” PLoS ONE, vol. 10, no. 4, Article ID e0121705, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Tentori, K. McCullough, R. D. Kilpatrick et al., “High rates of death and hospitalization follow bone fracture among hemodialysis patients,” Kidney International, vol. 85, no. 1, pp. 166–173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Hayashi, N. Joki, Y. Tanaka et al., “The FRAX® as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study,” Journal of Bone and Mineral Metabolism, vol. 33, no. 6, pp. 674–683, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Stenvinkel, J. J. Carrero, F. von Walden, T. A. Ikizler, and G. A. Nader, “Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies,” Nephrology Dialysis Transplantation, vol. 31, no. 7, pp. 1070–1077, 2016. View at Publisher · View at Google Scholar
  16. C. Delgado, S. Shieh, B. Grimes et al., “Association of self-reported frailty with falls and fractures among patients new to dialysis,” American Journal of Nephrology, vol. 42, no. 2, pp. 134–140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Maravic, A. Ostertag, P. Urena, and M. Cohen-Solal, “Dementia is a major risk factor for hip fractures in patients with chronic kidney disease,” Osteoporosis International, vol. 27, no. 4, pp. 1665–1669, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Desmet, C. Beguin, C. Swine, and M. Jadoul, “Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications,” American Journal of Kidney Diseases, vol. 45, no. 1, pp. 148–153, 2005. View at Google Scholar
  19. J. B. Wetmore, J. Liu, H. S. Wirtz et al., “Geovariation in fracture risk among patients receiving hemodialysis,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 8, pp. 1413–1421, 2016. View at Publisher · View at Google Scholar
  20. S. Moe, T. Drüeke, J. Cunningham et al., “Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, vol. 69, no. 11, pp. 1945–1953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, “Osteoporosis prevention, diagnosis, and therapy,” The Journal of the American Medical Association, vol. 285, no. 6, pp. 785–795, 2001. View at Publisher · View at Google Scholar
  22. M. L. Bouxsein, “Bone quality: where do we go from here?” Osteoporosis International, vol. 14, supplement 5, pp. S118–S127, 2003. View at Google Scholar
  23. D. Felsenberg and S. Boonen, “The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management,” Clinical Therapeutics, vol. 27, no. 1, pp. 1–11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. E. S. Siris, P. D. Miller, E. Barrett-Connor et al., “Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment,” Journal of the American Medical Association, vol. 286, no. 22, pp. 2815–2822, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Sornay-Rendu, F. Munoz, P. Garnero, F. Duboeuf, and P. D. Delmas, “Identification of osteopenic women at high risk of fracture: the OFELY study,” Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1813–1819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. S. C. E. Schuit, M. Van Der Klift, A. E. A. M. Weel et al., “Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study,” Bone, vol. 34, no. 1, pp. 195–202, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. E. M. Stein, A. Kepley, M. Walker et al., “Skeletal structure in postmenopausal women with osteopenia and fractures is characterized by abnormal trabecular plates and cortical thinning,” Journal of Bone and Mineral Research, vol. 29, no. 5, pp. 1101–1109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Bala, R. Zebaze, A. Ghasem-Zadeh et al., “Cortical porosity identifies women with osteopenia at increased risk for forearm fractures,” Journal of Bone and Mineral Research, vol. 29, no. 6, pp. 1356–1362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Malgo, N. A. T. Hamdy, S. E. Papapoulos, and N. M. Appelman-Dijkstra, “Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density,” Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 5, pp. 2039–2045, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, “KIDGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral bone disorder (CKD-MBD),” Kidney International, vol. 113, pp. S1–S130, 2009. View at Google Scholar
  31. R. C. Bucur, D. D. Panjwani, L. Turner, T. Rader, S. L. West, and S. A. Jamal, “Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis,” Osteoporosis International, vol. 26, no. 2, pp. 449–458, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. S. L. West, C. E. Lok, L. Langsetmo et al., “Bone mineral density predicts fractures in chronic kidney disease,” Journal of Bone and Mineral Research, vol. 30, no. 5, pp. 913–919, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Iimori, Y. Mori, W. Akita et al., “Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 345–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. R. H. Yenchek, J. H. Ix, M. G. Shlipak et al., “Bone mineral density and fracture risk in older individuals with CKD,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 7, pp. 1130–1136, 2012. View at Publisher · View at Google Scholar
  35. S. M. Moe, T. Drüeke, N. Lameire, and G. Eknoyan, “Chronic kidney disease–mineral-bone disorder: a new paradigm,” Advances in Chronic Kidney Disease, vol. 14, no. 1, pp. 3–12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. G. Vervloet, Z. A. Massy, V. M. Brandenburg et al., “Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders,” The Lancet Diabetes and Endocrinology, vol. 2, no. 5, pp. 427–436, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Parfitt, “A structural approach to renal bone disease,” Journal of Bone and Mineral Research, vol. 13, no. 8, pp. 1213–1220, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. S. M. Ott, “Review article: bone density in patients with chronic kidney disease stages 4-5,” Nephrology, vol. 14, no. 4, pp. 395–403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. T. L. Nickolas, M. B. Leonard, and E. Shane, “Chronic kidney disease and bone fracture: a growing concern,” Kidney International, vol. 74, no. 6, pp. 721–731, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. T. L. Nickolas, E. M. Stein, E. Dworakowski et al., “Rapid cortical bone loss in patients with chronic kidney disease,” Journal of Bone and Mineral Research, vol. 28, no. 8, pp. 1811–1820, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Kazama, R. Koda, S. Yamamoto, I. Narita, F. Gejyo, and A. Tokumoto, “Cancellous bone volume is an indicator for trabecular bone connectivity in dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 2, pp. 292–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. D. Rudser, I. H. de Boer, A. Dooley, B. Young, and B. Kestenbaum, “Fracture risk after parathyroidectomy among chronic hemodialysis patients,” Journal of the American Society of Nephrology, vol. 18, no. 8, pp. 2401–2407, 2007. View at Publisher · View at Google Scholar
  43. Y. Maruyama, M. Taniguchi, J. J. Kazama et al., “A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan,” Nephrology Dialysis Transplantation, vol. 29, no. 8, pp. 1532–1538, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Trombetti, C. Stoermann, T. Chevalley et al., “Alterations of bone microstructure and strength in end-stage renal failure,” Osteoporosis International, vol. 24, no. 5, pp. 1721–1732, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. L. Negri, E. E. Del Valle, M. B. Zanchetta et al., “Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients,” Osteoporosis International, vol. 23, no. 10, pp. 2543–2550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Fukagawa, J. J. Kazama, and T. Shigematsu, “Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases,” American Journal of Kidney Diseases, vol. 38, no. 4, supplement 1, pp. S152–S155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Iwasaki, H. Yamato, T. Nii-Kono et al., “Insufficiency of PTH action on bone in uremia,” Kidney International Supplements, no. 102, pp. S34–S36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Bover, P. Ureña, V. Brandenburg et al., “Adynamic bone disease: from bone to vessels in chronic kidney disease,” Seminars in Nephrology, vol. 34, no. 6, pp. 626–640, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. H. H. Malluche, H. Mawad, and M.-C. Monier-Faugere, “The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?” Nephrology Dialysis Transplantation, vol. 19, supplement 1, pp. i9–i13, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Sherrard, G. Hercz, Y. Pei et al., “The spectrum of bone disease in end-stage renal failure—an evolving disorder,” Kidney International, vol. 43, no. 2, pp. 436–442, 1993. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Iwasaki, J. J. Kazama, H. Yamato, and M. Fukagawa, “Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease,” Bone, vol. 48, no. 6, pp. 1260–1267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Atsumi, K. Kushida, K. Yamazaki, S. Shimizu, A. Ohmura, and T. Inoue, “Risk factors for vertebral fractures in renal osteodystrophy,” American Journal of Kidney Diseases, vol. 33, no. 2, pp. 287–293, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Piraino, T. Chen, L. Cooperstein, G. Segre, and J. Puschett, “Fractures and vertebral bone mineral density in patients with renal osteodystrophy,” Clinical Nephrology, vol. 30, no. 2, pp. 57–62, 1988. View at Google Scholar · View at Scopus
  54. A. H. Ng, S. Omelon, F. Variola et al., “Adynamic bone decreases bone toughness during aging by affecting mineral and matrix,” Journal of Bone and Mineral Research, vol. 31, no. 2, pp. 369–379, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Evenepoel, B. Meijers, L. Viaene et al., “Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1268–1276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Isakova, P. Wahl, G. S. Vargas et al., “Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease,” Kidney International, vol. 79, no. 12, pp. 1370–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Nakano, T. Hamano, N. Fujii et al., “Combined use of vitamin D status and FGF23 for risk stratification of renal outcome,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 810–819, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. I. Mirza, M. K. Karlsson, D. Mellström et al., “Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men,” Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 857–864, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. N. E. Lane, N. Parimi, M. Corr et al., “Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study,” Journal of Bone and Mineral Research, vol. 28, no. 11, pp. 2325–2332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Kanda, M. Yoshida, and S. Sasaki, “Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients,” BMC Nephrology, vol. 13, no. 1, article 122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Jovanovich, P. Bùžková, M. Chonchol et al., “Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. 3323–3331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Desjardins, S. Liabeuf, C. Renard et al., “FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages,” Osteoporosis International, vol. 23, no. 7, pp. 2017–2025, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Isakova, X. Cai, J. Lee et al., “Associations of FGF23 with change in bone mineral density and fracture risk in older individuals,” Journal of Bone and Mineral Research, vol. 31, no. 4, pp. 742–748, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Carrillo-López, S. Panizo, C. Alonso-Montes et al., “Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease,” Kidney International, vol. 90, no. 1, pp. 77–89, 2016. View at Publisher · View at Google Scholar
  65. S. K. Murali, P. Roschger, U. Zeitz, K. Klaushofer, O. Andrukhova, and R. G. Erben, “FGF23 regulates bone mineralization in a 1,25(OH)2D3 and Klotho-independent manner,” Journal of Bone and Mineral Research, vol. 31, no. 1, pp. 129–142, 2016. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Arasu, P. M. Cawthon, L.-Y. Lui et al., “Serum sclerostin and risk of hip fracture in older caucasian women,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. 2027–2032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. M.-S. M. Ardawi, A. A. Rouzi, S. A. Al-Sibiani, N. S. Al-Senani, M. H. Qari, and S. A. Mousa, “High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study,” Journal of Bone and Mineral Research, vol. 27, no. 12, pp. 2592–2602, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Garnero, E. Sornay-Rendu, F. Munoz, O. Borel, and R. D. Chapurlat, “Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study,” Osteoporosis International, vol. 24, no. 2, pp. 489–494, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Szulc, C. Bertholon, O. Borel, F. Marchand, and R. Chapurlat, “Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study,” Journal of Bone and Mineral Research, vol. 28, no. 4, pp. 855–864, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Sabbagh, F. G. Graciolli, S. O'Brien et al., “Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy,” Journal of Bone and Mineral Research, vol. 27, no. 8, pp. 1757–1772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Cejka, J. Herberth, A. J. Branscum et al., “Sclerostin and dickkopf-1 in renal osteodystrophy,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 877–882, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Thambiah, R. Roplekar, P. Manghat et al., “Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness,” Calcified Tissue International, vol. 90, no. 6, pp. 473–480, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Pelletier, L. Dubourg, M.-C. Carlier, A. Hadj-Aissa, and D. Fouque, “The relation between renal function and serum sclerostin in adult patients with CKD,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 5, pp. 819–823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. J. C. Ferreira, G. O. Ferrari, K. R. Neves et al., “Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease—role of sclerostin?” PLoS ONE, vol. 8, no. 11, Article ID e79721, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. C. L. Newman, N. X. Chen, E. Smith et al., “Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions,” Bone, vol. 77, pp. 50–56, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Coen, D. Mantella, M. Manni et al., “25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy,” Kidney International, vol. 68, no. 4, pp. 1840–1848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Ambrus, C. Almasi, K. Berta et al., “Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis,” International Urology and Nephrology, vol. 43, no. 2, pp. 475–482, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. H. A. Bischoff-Ferrari, W. C. Willett, J. B. Wong et al., “Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials,” Archives of Internal Medicine, vol. 169, no. 6, pp. 551–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Scragg, “Vitamin D and public health: an overview of recent research on common diseases and mortality in adulthood,” Public Health Nutrition, vol. 14, no. 9, pp. 1515–1532, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. H. A. Bischoff-Ferrari, W. C. Willett, E. J. Orav et al., “A pooled analysis of vitamin D dose requirements for fracture prevention,” The New England Journal of Medicine, vol. 367, no. 1, pp. 40–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. E. P. Paschalis, R. Mendelsohn, and A. L. Boskey, “Infrared assessment of bone quality: a review,” Clinical Orthopaedics and Related Research, vol. 469, no. 8, pp. 2170–2178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. M. D. Morris and G. S. Mandair, “Raman assessment of bone quality,” Clinical Orthopaedics and Related Research, vol. 469, no. 8, pp. 2160–2169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Iwasaki, J. J. Kazama, H. Yamato, H. Shimoda, and M. Fukagawa, “Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease,” Bone, vol. 57, no. 2, pp. 477–483, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Iwasaki, J. J. Kazama, H. Yamato, A. Matsugaki, T. Nakano, and M. Fukagawa, “Altered material properties are responsible for bone fragility in rats with chronic kidney injury,” Bone, vol. 81, pp. 247–254, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. C. L. Newman, S. M. Moe, N. X. Chen et al., “Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease,” PLoS ONE, vol. 9, no. 6, Article ID e99262, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. H. H. Malluche, D. S. Porter, M.-C. Monier-Faugere, H. Mawad, and D. Pienkowski, “Differences in bone quality in low- and high-turnover renal osteodystrophy,” Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 525–532, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Isaksson, M. J. Turunen, L. Rieppo et al., “Infrared spectroscopy indicates altered bone turnover and remodeling activity in renal osteodystrophy,” Journal of Bone and Mineral Research, vol. 25, no. 6, pp. 1360–1366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Mitome, H. Yamamoto, M. Saito, K. Yokoyama, K. Marumo, and T. Hosoya, “Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients,” Calcified Tissue International, vol. 88, no. 6, pp. 521–529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. C. Aoki, K. Uto, K. Honda, Y. Kato, and H. Oda, “Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy,” Laboratory Investigation, vol. 93, no. 11, pp. 1170–1183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Nakano, K. Kaibara, Y. Tabata et al., “Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system,” Bone, vol. 31, no. 4, pp. 479–487, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Himmelfarb, “Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy,” Seminars in Dialysis, vol. 22, no. 6, pp. 636–643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Iwasaki-Ishizuka, H. Yamato, T. Nii-Kono, K. Kurokawa, and M. Fukagawa, “Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone,” Nephrology Dialysis Transplantation, vol. 20, no. 9, pp. 1904–1911, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. J. J. Kazama, S. Yamamoto, I. Narita, and S. Kurihara, “Nuclear chromatin-concentrated osteoblasts in renal bone diseases,” Therapeutic Apheresis and Dialysis, vol. 15, no. 1, pp. 9–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Nii-Kono, Y. Iwasaki, M. Uchida et al., “Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells,” Kidney International, vol. 71, no. 8, pp. 738–743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Tanaka, Y. Iwasaki, H. Yamato et al., “p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways,” Bone, vol. 56, no. 2, pp. 347–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Yano, T. Yamaguchi, I. Kanazawa et al., “The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure,” Nephrology Dialysis Transplantation, vol. 22, no. 11, pp. 3160–3165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Mozar, L. Louvet, C. Godin et al., “Indoxyl sulphate inhibits osteoclast differentiation and function,” Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2176–2181, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Bacchetta, S. Boutroy, L. Juillard et al., “Bone imaging and chronic kidney disease: will high-resolution peripheral tomography improve bone evaluation and therapeutic management?” Journal of Renal Nutrition, vol. 19, no. 1, pp. 44–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. Z. Seref-Ferlengez, O. D. Kennedy, and M. B. Schaffler, “Bone microdamage, remodeling and bone fragility: how much damage is too much damage?” BoneKEy Reports, vol. 4, article 644, 2015. View at Publisher · View at Google Scholar
  100. H. H. Malluche, D. S. Porter, and D. Pienkowski, “Evaluating bone quality in patients with chronic kidney disease,” Nature Reviews Nephrology, vol. 9, no. 11, pp. 671–680, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. C. R. Dunstan, N. M. Somers, and R. A. Evans, “Osteocyte death and hip fracture,” Calcified Tissue International, vol. 53, supplement 1, pp. S113–S117, 1993. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Power, B. S. Noble, N. Loveridge, K. L. Bell, N. Rushton, and J. Reeve, “Osteocyte lacunar occupancy in the femoral neck cortex: an association with cortical remodeling in hip fracture cases and controls,” Calcified Tissue International, vol. 69, no. 1, pp. 13–19, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Delgado-Calle, J. Arozamena, R. García-Renedo et al., “Osteocyte deficiency in hip fractures,” Calcified Tissue International, vol. 89, no. 4, pp. 327–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. F. R. Bringhurst, “PTH receptors and apoptosis in osteocytes,” Journal of Musculoskeletal Neuronal Interactions, vol. 2, no. 3, pp. 245–251, 2002. View at Google Scholar · View at Scopus
  105. C. Donadio, M. Ardini, A. Lucchesi, E. Donadio, and T. Cantor, “Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status?” Clinical Nephrology, vol. 67, no. 3, pp. 131–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. S. M. Ott, “Bisphosphonate safety and efficacy in chronic kidney disease,” Kidney International, vol. 82, no. 8, pp. 833–835, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. R. C. Güerri-Fernández, X. Nogués, J. M. Quesada Gómez et al., “Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls,” Journal of Bone and Mineral Research, vol. 28, no. 1, pp. 162–168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Gourion-Arsiquaud, M. R. Allen, D. B. Burr, D. Vashishth, S. Y. Tang, and A. L. Boskey, “Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity,” Bone, vol. 46, no. 3, pp. 666–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. E. Shane, D. Burr, B. Abrahamsen et al., “Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research,” Journal of Bone and Mineral Research, vol. 29, no. 1, pp. 1–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. Z. Mahjoub, S. Jean, J.-T. Leclerc et al., “Incidence and characteristics of atypical femoral fractures: clinical and geometrical data,” Journal of Bone and Mineral Research, vol. 31, no. 4, pp. 767–776, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Sato, N. Kondo, Y. Wada et al., “The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates,” Osteoporosis International, vol. 27, no. 3, pp. 1217–1225, 2016. View at Publisher · View at Google Scholar · View at Scopus
  112. P. Anagnostis and J. C. Stevenson, “Bisphosphonate drug holidays-when, why and for how long?” Climacteric, vol. 18, supplement 2, pp. 32–38, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. S. A. Jamal, Ö. Ljunggren, C. Stehman-Breen et al., “Effects of denosumab on fracture and bone mineral density by level of kidney function,” Journal of Bone and Mineral Research, vol. 26, no. 8, pp. 1829–1835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. R. Hiramatsu, Y. Ubara, N. Sawa et al., “Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial,” American Journal of Kidney Diseases, vol. 66, no. 1, pp. 175–177, 2015. View at Publisher · View at Google Scholar · View at Scopus
  115. G. A. Block, H. G. Bone, L. Fang, E. Lee, and D. Padhi, “A single-dose study of denosumab in patients with various degrees of renal impairment,” Journal of Bone and Mineral Research, vol. 27, no. 7, pp. 1471–1479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Ishani, T. Blackwell, S. A. Jamal, S. R. Cummings, and K. E. Ensrud, “The effect of raloxifene treatment in postmenopausal women with CKD,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1430–1438, 2008. View at Google Scholar
  117. M. L. Melamed, T. Blackwell, J. Neugarten et al., “Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis,” Kidney International, vol. 79, no. 2, pp. 241–249, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Sumida, Y. Ubara, J. Hoshino et al., “Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study,” Osteoporosis International, vol. 27, no. 4, pp. 1441–1450, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Mitsopoulos, E. Ginikopoulou, D. Economidou et al., “Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study,” American Journal of Nephrology, vol. 36, no. 3, pp. 238–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. D. Cejka, K. Kodras, T. Bader, and M. Haas, “Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study,” Kidney and Blood Pressure Research, vol. 33, no. 3, pp. 221–226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. M. R. McClung, A. Grauer, S. Boonen et al., “Romosozumab in postmenopausal women with low bone mineral density,” The New England Journal of Medicine, vol. 370, no. 5, pp. 412–420, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. C. P. Recknor, R. R. Recker, C. T. Benson et al., “The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density,” Journal of Bone and Mineral Research, vol. 30, no. 9, pp. 1717–1725, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. C. Graeff, G. M. Campbell, J. Peña et al., “Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis,” Bone, vol. 81, pp. 364–369, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Cejka, R. Marculescu, N. Kozakowski et al., “Renal elimination of sclerostin increases with declining kidney function,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 1, pp. 248–255, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Desjardins, S. Liabeuf, R. B. Oliveira et al., “Uremic toxicity and sclerostin in chronic kidney disease patients,” Nephrologie et Therapeutique, vol. 10, no. 6, pp. 463–470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  126. R. Koos, V. Brandenburg, A. H. Mahnken et al., “Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study,” The Journal of Heart Valve Disease, vol. 22, no. 3, pp. 317–325, 2013. View at Google Scholar · View at Scopus
  127. M. Kanbay, D. Siriopol, M. Saglam et al., “Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 10, pp. E1854–E1861, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Drechsler, P. Evenepoel, M. G. Vervloet et al., “High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study,” Nephrology Dialysis Transplantation, vol. 30, no. 2, pp. 288–293, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. S. M. Moe, S. Abdalla, G. M. Chertow et al., “Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial,” Journal of the American Society of Nephrology, vol. 26, no. 6, pp. 1466–1475, 2015. View at Publisher · View at Google Scholar · View at Scopus
  130. G. J. Behets, G. Spasovski, L. R. Sterling et al., “Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism,” Kidney International, vol. 87, no. 4, pp. 846–856, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. S. Yamamoto, R. Kido, Y. Onishi et al., “Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients,” PLoS ONE, vol. 10, no. 4, Article ID e0122691, 2015. View at Publisher · View at Google Scholar · View at Scopus
  132. C. S. Rajapakse, M. B. Leonard, Y. A. Bhagat, W. Sun, J. F. Magland, and F. W. Wehrli, “Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation,” Radiology, vol. 262, no. 3, pp. 912–920, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. B. Bielesz, J. M. Patsch, L. Fischer et al., “Cortical porosity not superior to conventional densitometry in identifying hemodialysis patients with fragility fracture,” PLoS ONE, vol. 12, no. 2, Article ID e0171873, 2017. View at Publisher · View at Google Scholar
  134. T. Jenkins, L. V. Coutts, S. D'Angelo et al., “Site-dependent reference point microindentation complements clinical measures for improved fracture risk assessment at the human femoral neck,” Journal of Bone and Mineral Research, vol. 31, no. 1, pp. 196–203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Ketteler, G. J. Elder, P. Evenepoel et al., “Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: improving Global Outcomes controversies conference,” Kidney International, vol. 87, no. 3, pp. 502–508, 2015. View at Publisher · View at Google Scholar · View at Scopus